---
document_datetime: 2024-12-02 15:38:58
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sancuso-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sancuso-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.1564388
conversion_datetime: 2025-12-24 21:55:52.467858
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sancuso

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| T/0064               | Transfer of Marketing Authorisation                                           | 30/10/2024                          | 22/11/2024                                  | SmPC, Labelling and PL           |                                   |
| PSUSA/10101 /202310  | Periodic Safety Update EU Single assessment - granisetron (transdermal patch) | 13/06/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0062/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/07/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0061     | Update of sections 4.4, 4.6, 4.7, 4.8, 4.10 and 5.3 of the SmPC in order to add 'Serotonin syndrome' and 'Application site Reactions' to the list of adverse drug reactions (ADRs) with frequency unknow; as well as 'Application site Irritation' with frequency 'Uncommon' based on post-marketing data and literature. The MAH also proposes to update sections 4.4 and 4.5 of the SmPC to add drug-drug interaction information with buprenorphine/Opioids and serotonergic medicinal products based on post- marketing data and literature. The Package Leaflet has been updated accordingly. The RMP version 5 has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 09/02/2023   | 25/01/2024 | SmPC and PL | Section 4.4 New information added Gastrointestinal disorders: 'Granisenton may mask a progressive ileus and/or gastric distension caused by an underlying condition' Serotonin syndrome: 'There have also been reports of possible drug-drug interactions between buprenorphine/Opioids and serotonergic medicinal products leading to serotonin syndrome' Skin Reactions: 'In clinical studies with granisetron transdermal patch, application site reactions generally mild in intensity were reported and did not lead to discontinuation of use. If severe reactions, or a generalised skin reaction occur (e.g. allergic rash, including erythematous, macular, papular rash or pruritus), the transdermal patch must be removed'. Potential for drug abuse and dependence 'Granisetron has no known potential for abuse and dependence' Section 4.7 Text replaced: 'The effect of SANCUSO on the ability to drive or operate machinery has not been studied' Section 4.8 Text replaced: Serotonin syndrome was added as ADR with frequency |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                |            |     | reports of serotonin syndrome following concomitant use of 5 HT3 antagonists with Buprenorphine, opiods SSRIs, SNRIs and serotonergic medicinal products. (section 4.5 also updated) Section 5.3 New text added Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. These studies did not reveal any evidence of impaired fertility or harm to the foetus due to granisetron. Fertility was unaffected following granisetron treatment in rat (sentence transferred from 4.6) For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10101 /202010 | Periodic Safety Update EU Single assessment - granisetron (transdermal patch)                                                                                                                                                                                                  | 10/06/2021 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0058             | B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                         | 14/01/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0059/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place A.4 - Administrative change - Change in the name | 11/12/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                                  |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| PSUSA/10101 /201910 | Periodic Safety Update EU Single assessment - granisetron (transdermal patch)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/05/2020 | n/a        |                                  | PRAC Recommendation - maintenance |
| II/0056/G           | This was an application for a group of variations. Update of the SmPC section 5.2. to revise the statement regarding data in paediatric patients. The RMP has also been updated to implement RMP template EMA/PRAC/613102/2015 Rev 2 and includes the addition or deletion of safety concerns (identified risks, potential risks, missing information) not previously assessed or requested by a competent authority. The MAH took the opportunity to update the Pregnancy information in section 4.6 of Annex I to align with the QRD statements as of the QRD product information template v10.1. Minor QRD updates have also been implemented in the annex II in line with version 10.1 of the QRD template. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of | 30/04/2020 | 16/04/2021 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |    |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUSA/10101 /201810 | Periodic Safety Update EU Single assessment - granisetron (transdermal patch)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/05/2019 | n/a        |    | PRAC Recommendation - maintenance |
| N/0055              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/03/2019 | 16/04/2021 | PL |                                   |
| II/0053/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 24/01/2019 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

|                     | applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test                                                                                                                                                                                                                                         |            |            |                        |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| T/0052              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 02/07/2018 | 19/07/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/10101 /201710 | Periodic Safety Update EU Single assessment - granisetron (transdermal patch)                                                                                                                                                                                                                                                                                                                                                                                                                           | 17/05/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0050              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                        | 14/06/2017 | 19/07/2018 | PL                     |                                   |
| PSUSA/10101 /201610 | Periodic Safety Update EU Single assessment - granisetron (transdermal patch)                                                                                                                                                                                                                                                                                                                                                                                                                           | 05/05/2017 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0049/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 21/03/2017 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test                                                                                                                               |            |            |                                  |                                                                                                                                                                                                                                                                       |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0047              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                              | 10/11/2016 | 09/01/2017 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Sancuso in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0046           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                           | 02/06/2016 | 09/01/2017 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                       |
| PSUSA/10101 /201510 | Periodic Safety Update EU Single assessment - granisetron (transdermal patch)                                                                                                                                                                                                                                                                        | 13/05/2016 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| N/0045              | Update of the package leaflet with revised contact details of the local representative for Spain. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                   | 18/02/2016 | 09/01/2017 | PL                               |                                                                                                                                                                                                                                                                       |
| IB/0043/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a | 03/02/2016 | n/a        |                                  |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| starting material/reagent/intermediate variation B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.b.1.b - Change in the and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in the and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.2.e - Change in   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                    |            |            |             |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IAIN/0042           | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                   | 09/12/2015 | n/a        |             |                                   |
| PSUSA/10101 /201504 | Periodic Safety Update EU Single assessment - granisetron (transdermal patch)                                                                                                                                                                     | 06/11/2015 | n/a        |             | PRAC Recommendation - maintenance |
| IAIN/0041           | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                   | 24/09/2015 | n/a        |             |                                   |
| N/0039              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                  | 25/06/2015 | 25/01/2016 | PL          |                                   |
| PSUSA/10101 /201410 | Periodic Safety Update EU Single assessment - granisetron (transdermal patch)                                                                                                                                                                     | 07/05/2015 | n/a        |             | PRAC Recommendation - maintenance |
| N/0038              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                  | 16/02/2015 | 25/01/2016 | PL          |                                   |
| IB/0037/G           | This was an application for a group of variations. B.II.e.6.z - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Other variation B.II.b.3.z - Change in the manufacturing process of | 29/01/2015 | 25/01/2016 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | the finished or intermediate product - Other variation B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             |                                                                                                                                                  |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0034 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20/11/2014 | 15/01/2015 | SmPC and PL | Please refer to Sancuso PSUV-34 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| IB/0035/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 13/01/2015 | n/a        |             |                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.d.1.b.3 - Stability of AS - Change in the storage conditions - Change in storage conditions of the AS   |            |            |             |                                                                                                                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0030 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/05/2014 | 18/07/2014 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0030. |
| IA/0031   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 11/04/2014 | n/a        |             |                                                                                                                                   |
| IAIN/0029 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/11/2013 | 18/07/2014 | SmPC and PL |                                                                                                                                   |
| N/0028    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 02/08/2013 | 18/07/2014 | PL          |                                                                                                                                   |
| II/0027   | Introduction of a site specific alternate process and controls for the manufacture of the finished product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 27/06/2013 | n/a        |             |                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.3.b - Change in the manufacturing process of the finished product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |          |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|
| IB/0026/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.a.2.z - Change in the shape or dimensions of the pharmaceutical form - Other variation B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.I.b.2.e - Change in test procedure for AS or | 18/04/2013 | n/a | starting |

<div style=\"page-break-after: always\"></div>

|           | or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |     | changes to a test procedure   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------|
| IB/0022/G | This was an application for a group of variations. B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                        | 18/04/2013 | n/a |                               |
| IB/0024/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the product - Other variation                                                                                                                                                                                                             | 15/03/2013 | n/a | finished                      |

<div style=\"page-break-after: always\"></div>

| IB/0025/G   | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure   | 08/03/2013   | n/a   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0021/G   | This was an application for a group of variations. B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.z - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                               | 08/03/2013   | n/a   |

<div style=\"page-break-after: always\"></div>

|           | limits of the immediate packaging of the product - Other variation                                                                                                                                                                                                           |            |     | and/or finished        |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| IB/0013   | B.II.c.1.f - Change in the specification parameters and/or limits of an excipient - Addition or replacement (excluding biological or immunological product) of a specification parameter as a result of a safety or quality issue                                            | 10/01/2013 | n/a |                        |
| IAIN/0020 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                               | 19/12/2012 | n/a |                        |
| IB/0019   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                       | 18/12/2012 | n/a |                        |
| IB/0018   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                       | 17/12/2012 | n/a |                        |
|           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 12/12/2012 | n/a | IA/0017/G              |
| IB/0002/G | This was an application for a group of variations. any part of the (primary)                                                                                                                                                                                                 | 29/11/2012 | n/a | B.II.e.6.b - Change in |

<div style=\"page-break-after: always\"></div>

|         | packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation   |            |     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0014 | B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                                                         | 22/11/2012 | n/a |
| IB/0012 | B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                                                         | 22/11/2012 | n/a |
| IB/0008 | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                             | 13/11/2012 | n/a |
| IB/0007 | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                             | 13/11/2012 | n/a |
| IA/0011 | B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits                                                                                                                                                 | 12/11/2012 | n/a |
| IA/0010 | B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits                                                                                                                                                 | 12/11/2012 | n/a |

<div style=\"page-break-after: always\"></div>

| IA/0009   | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                        | 12/11/2012   | n/a   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IA/0006   | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                 | 08/11/2012   | n/a   |
| IB/0005/G | This was an application for a group of variations. B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.z - Change in control of excipients in the Finished Product - Other variation | 08/11/2012   | n/a   |